[Form 4] BIO-TECHNE Corp Insider Trading Activity

Rhea-AI Filing Summary

Bio-Techne (TECH) reported insider transactions by its CFO on 11/03/2025. The executive acquired company stock through RSU vesting and surrendered shares to cover taxes.

Two RSU conversions (code M) added 13,159 shares and 11,545 shares at $0. A tax withholding transaction (code F) disposed of 11,865 shares at $62.57. Following these transactions, the CFO directly owned 142,722 shares.

These actions reflect routine equity award vesting and associated tax settlement rather than an open‑market purchase or sale.

Insights

Insider transactions analyst

Routine RSU vesting with tax withholding; minimal impact.

The CFO reported equity award activity on 11/03/2025: RSUs vested (code M) adding 13,159 and 11,545 common shares at $0, and a tax withholding (code F) reduced holdings by 11,865 shares at $62.57.

Form 4 codes indicate non‑open‑market events tied to compensation. Such transactions generally do not signal changes in executive sentiment.

Post‑transaction holdings are 142,722 shares directly. Actual impact on float is minor and depends on award schedules and future vesting mechanics disclosed in the award footnotes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hippel James

(Last) (First) (Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
11/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/03/2025		M		13,159	A	$0	143,042	D
Common Stock	11/03/2025		M		11,545	A	$0	154,587	D
Common Stock	11/03/2025		F		11,865	D	$62.57	142,722	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$47.6							(1)	08/07/2026	Common Stock	186,068		186,068	D
Stock Options (Right to Buy)	$66.97							(1)	08/05/2027	Common Stock	167,328		167,328	D
Stock Options (Right to Buy)	$120.46							(1)	08/06/2028	Common Stock	40,536		40,536	D
Stock Options (Right to Buy)	$94.52							(3)	08/15/2029	Common Stock	45,220		45,220	D
Performance Restricted Stock Units	(2)							(4)	(4)	Common Stock	13,865		13,865	D
Performance Stock Options (Right to Buy)	$84.61							(4)	08/15/2030	Common Stock	37,314		37,314	D
Stock Options (Right to Buy)	$84.61							(5)	08/15/2030	Common Stock	45,923		45,923	D
Restricted Stock Units	(2)	11/03/2025		M			13,159	(6)	(6)	Common Stock	13,159	$0	0	D
Performance Restricted Stock Units	(2)							(7)	(7)	Common Stock	24,062		24,062	D
Restricted Stock Units	(2)							(8)	(8)	Common Stock	4,010		8,021	D
Stock Options (Right to Buy)	$74.91							(9)	08/15/2034	Common Stock	32,417		32,417	D
Restricted Stock Units	(2)	11/03/2025		M			11,545	(10)	(10)	Common Stock	11,545	$0	23,089	D
Performance Restricted Stock Units	(2)							(11)	(11)	Common Stock	29,420		29,420	D
Restricted Stock Units	(2)							(12)	(12)	Common Stock	14,710		14,710	D
Stock Options (Right to Buy)	$53.6							(13)	08/15/2035	Common Stock	37,632		37,632	D

Explanation of Responses:

1. Fully exercisable.

2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.

3. Options to purchase 11,305 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.

4. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

5. Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.

6. 13,159 restricted stock units vest on 11/1/2025.

7. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

8. 4,010 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 4,011 restricted stock units vest on 8/15/2027.

9. Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028.

10. 11,545 restricted stock units vest on each of 11/1/2025 and 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.

11. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

12. 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028.

13. Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.

	/s/ Andrew Nick as Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed	11/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BIO-TECHNE (TECH) disclose in this Form 4?

The CFO reported RSU vesting (code M) adding 13,159 and 11,545 shares at $0, and a tax withholding transaction (code F) disposing of 11,865 shares at $62.57 on 11/03/2025.

How many BIO-TECHNE (TECH) shares does the CFO hold after the transactions?

Following the reported transactions, the CFO directly owned 142,722 shares.

What do the Form 4 transaction codes M and F mean for TECH?

Code M indicates conversion of derivative securities (e.g., RSUs) into common stock; code F indicates shares withheld or tendered to satisfy tax obligations.

Were these open-market buys or sells of TECH stock?

No. The acquisitions were RSU vesting at $0, and the disposition was for tax withholding, not an open‑market trade.

What prices were involved in the TECH transactions?

RSU conversions occurred at $0. The tax withholding disposition price was $62.57 per share.

Do these transactions change BIO-TECHNE’s cash position?

No. RSU vesting and tax withholding are compensation-related equity movements and do not represent company cash inflows or outflows.